1-(3,4-dimethoxybenzoyl)-4-(3-formyl-4-nitrophenyl)piperazine | 81840-07-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(3,4-dimethoxybenzoyl)-4-(3-formyl-4-nitrophenyl)piperazine
• 英文别名: 2-nitro-5-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]benzaldehyde；5-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-2-nitrobenzaldehyde
• CAS: 81840-07-5
• 化学式: C₂₀H₂₁N₃O₆
• 分子量: 399.403
• InChiKey: DIWRKYVGQWXMSU-UHFFFAOYSA-N

物化性质

• 熔点：
  196-198 °C
• 沸点：
  642.6±55.0 °C(Predicted)
• 密度：
  1.325±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  105
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-(3,4-dimethoxybenzoyl)-4-(3-formyl-4-nitrophenyl)piperazine 在 palladium on activated charcoal sodium tetrahydroborate 、 氢气 作用下， 以 甲醇 、 乙醇 、 氯仿 为溶剂， 反应 14.0h， 生成 6-<4-(3,4-dimethoxybenzoyl)-1-piperazinyl>-3,4-dihydro-3-methyl-1H-quinazoline-2-thione
  参考文献：
  名称：

  正性肌力药的研究。VI。1-芳族环取代的4-（3,4-二甲氧基苯甲酰基）哌嗪衍生物的合成。

  摘要：

  合成了一系列带有1-芳环取代的4-(3,4-二甲氧基苯甲酰)哌嗪化合物，并对其在大犬心脏上的正性肌力活性进行了研究。其中，6-[4-(3,4-二甲氧基苯甲酰)-1-哌嗪基]-3-甲基-1H,3H-喹唑啉-2,4-二酮展现出强大的活性。

  DOI：

  10.1248/cpb.36.2401
• 作为产物：
  描述：

  5-氯-2-硝基苯甲醛 在 吡啶 、 对甲苯磺酸 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 25.5h， 生成 1-(3,4-dimethoxybenzoyl)-4-(3-formyl-4-nitrophenyl)piperazine
  参考文献：
  名称：

  Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility

  摘要：

  Two series of 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives incorporating an additional site for acid salt formation were synthesized and evaluated as inhibitors of human blood platelet cAMP phosphodiesterase (PDE) and ADP-induced platelet aggregation. The objective of this study was to identify compounds that blended potent biological activity with a satisfactory level of aqueous solubility. From a series of 7-aminoimidazo[4,5-b]quinolin-2-ones, biological and physical properties were optimally combined in the 1-piperidinyl derivative 11c. However, this compound offered no significant advantage over earlier studied compounds as an antithrombotic agent in an animal model of small vessel thrombosis. A series of 7-alkoxy alkanoic piperazinamide derivatives, in which the additional basic nitrogen atom was remote from the heterocyclic nucleus and accommodated in a secondary binding region of the cAMP PDE enzyme, demonstrated greater intrinsic cAMP PDE inhibitory activity. Structural modifications of this series focused on variation of the piperazine substituent and side-chain length. The lipophilicity of the N-substituent influenced biological potency and aqueous solubility, with substituents of seven carbon atoms or less generally providing acceptable solubility properties. The N-(cyclohexylmethyl)piperazinamide 21h was identified from this series of compounds as a potent inhibitor of platelet cAMP PDE, IC50 = 0.4 nM, and ADP-induced platelet aggregation, IC50 = 0.51-mu-M after a 3-min exposure and 0.1-mu-M after a 15-min exposure of platelet-rich plasma to the drug. Evaluation of 21h and representative analogues in vivo using a rabbit model of small vessel thrombosis revealed significantly greater antithrombotic efficacy compared to that of previously studied compounds with similar intrinsic biological activity measured in vitro but inferior aqueous solubility.

  DOI：

  10.1021/jm00092a020

文献信息

• Piperazinylcarbostyril compounds
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04415572A1

  公开（公告）日：1983-11-15

  A piperazinylcarbostyril compound of the formula (I) ##STR1## wherein R.sup.1 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, or a phenyl-lower alkyl group; R.sup.2 represents a hydrogen atom or a lower alkoxy group; R.sup.3 represents a hydrogen atom, a lower alkanoyl group, a furoyl group, a pyridylcarbonyl group, a lower alkanesulfonyl group, a lower alkoxycarbonyl group, a lower alkoxycarbonyl-lower alkyl group, a phenylsulfonyl group which may be substituted with a lower alkyl group on the benzene ring thereof, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a phenylcarbonyl group, a phenyl-lower alkyl group or a phenyl-lower alkanoyl group where each of said phenylcarbonyl group, phenyl-lower alkyl group and phenyl-lower alkanoyl group may be substituted with 1 to 3 of a lower alkoxy group, a halogen atom, a lower alkyl group, a cyano group, a nitro group, an amino group, a hydroxy group, a lower alkanoylamino group, a lower alkylthio group and a lower alkanoyloxy group, or with a lower alkylenedioxy group on the benzene ring thereof; and the bonding between the 3- and 4-positions of the carbostyril nucleus is a single bond or a double bond; or its pharmaceutically acceptable salt, useful as a cardiotonic agent.

  化合物的中文翻译如下： 一种具有以下结构式（I）的哌嗪基羧基喹啉化合物 其中R.sup.1代表氢原子、较低的烷基基团、较低的烯基基团、较低的炔基基团或苯基-较低的烷基基团；R.sup.2代表氢原子或较低的烷氧基团；R.sup.3代表氢原子、较低的烷酰基团、呋喃酰基团、吡啶基羰基团、较低的烷基磺酰基团、较低的烷氧羰基团、较低的烷氧羰基-较低的烷基基团、苯基磺酰基团，其在苯环上可能被较低的烷基基团取代，较低的烷基基团、较低的烯基基团、较低的炔基基团、苯基羰基团、苯基-较低的烷基基团或苯基-较低的烷酰基团，其中所述的苯基羰基团、苯基-较低的烷基基团和苯基-较低的烷酰基团中的每一个可能被1至3个较低的烷氧基团、卤原子、较低的烷基基团、氰基、硝基、氨基、羟基、较低的烷基酰氨基基团、较低的烷基硫基团和较低的烷基氧基团，或在其苯环上与较低的烷基二氧基基团取代；以及羧基喹啉核的3-位和4-位之间的键合是单键或双键；或其药学上可接受的盐，用作心力衰竭药物。
• Aminoimidazoquinoline derivatives
  申请人：Bristol-Myers Squibb Company

  公开号：EP0252503A1

  公开（公告）日：1988-01-13

  Novel series of 2,3-dihydro-2-oxo-1H-imidazo­[4,5-b]quinolinyl amine derivatives of Formula wherein R₁ is hydrogen, lower alkyl; R₂ is hydrogen, lower alkyl, lower alkoxy, halogen; R₃ is hydrogen, lower alkyl; R₄ is hydrogen, lower alkyl, alkanoyl, phenylalkanoyl wherein phenyl is optionally substituted with halogen, lower alkyl, lower alkoxy; R₃ and R₄ are joined together to form morpholinyl, piperidinyl or pyrrolidinyl optionally substituted with -CO₂R₅ or -NR₅R₆ wherein R₅ is hydrogen or lower alkyl, and R₆ is hydrogen, lower alkyl, cycloalkyl; 4-R₇-piperazinyl wherein R₇ is -CO₂R₈ wherein R₈ is lower alkyl, phenyl optionally substituted with up to 2 halogen, lower alkyl or lower alkoxy; phenylalkanoyl of 7 to 10 carbon wherein phenyl is unsubstituted or independently substituted with up to 2 halogen, lower alkyl, lower alkoxy. The compounds are cyclic AMP phosphodiesterase inhibitors and are particularly useful as inhibitors of blood platelet aggregation and/or as cardiotonic agents.

  式中 2,3-二氢-2-氧代-1H-咪唑并[4,5-b]喹啉胺衍生物新系列 其中 R₁ 是氢、低级烷基；R₂ 是氢、低级烷基、低级烷氧基、卤素；R₃ 是氢、低级烷基；R₄ 是氢、低级烷基、烷酰基、苯基烷酰基，其中苯基可选择被卤素、低级烷基、低级烷氧基取代；R₃ 和 R₄ 连接在一起形成吗啉基、哌啶基或吡咯烷基，其中苯基可选择被 -CO₂R₅ 取代，或 -4-R₇-哌嗪基，其中 R₇ 是 -CO₂R₈ ，其中 R₈ 是低级烷基，苯基可选择被最多 2 个卤素、低级烷基或低级烷氧基取代；碳原子数为 7 至 10 的苯基烷酰基，其中苯基未被取代或独立地被最多 2 个卤素、低级烷基或低级烷氧基取代。这些化合物是环 AMP 磷酸二酯酶抑制剂，尤其可用作血小板聚集抑制剂和/或强心剂。
• MEANWELL, NICHOLAS A.;WRIGHT, JOHN J.
  作者：MEANWELL, NICHOLAS A.、WRIGHT, JOHN J.

  DOI：——

  日期：——
• TOMINAGA, MICHIAKI;YANG, YUNG, H.;OGAWA, HIDENORI;NAKAGAWA, KAZUYUKI
  作者：TOMINAGA, MICHIAKI、YANG, YUNG, H.、OGAWA, HIDENORI、NAKAGAWA, KAZUYUKI

  DOI：——

  日期：——
• ——
  作者：TOMINAGA MITIAKI、 OGAVA XIDEHNORI、 FUDZIOKA TAKAFUMI、 EHJ KADZUESI、 NAKAG+

  DOI：——

  日期：——